Modulate Bio
Modulate Bio is advancing a new generation of fine-tuned neuro-medicines to treat a range of neurological disorders. Modulate Bio’s platform enables them to precisely treat neurological disorders like Essential Tremor, epilepsy and anxiety by restoring healthy brain receptor function, without overactivating. Modulate Bio has achieved in vivo proof-of-concept in mice and are close to identifying…
-
Dr. Dario Doller, PhD
CSO
-
Kevin Hodgetts, PhD
SAB Chair
RedPoint Oncology
RedPoint Oncology is a targeted precision oncology company, leveraging next-generation antibody-drug conjugates to develop best-in-class therapies for lethal solid tumors with no cure.
-
Mengdie Wang, PhD
Co-founder, CEO
-
Arthur Mercurio, PhD
Co-founder/Advisor
Vova Ida Therapeutics, Inc
Vova Ida Therapeutics, Inc. (VIT) is a preclinical-stage biotech company developing therapeutics to prevent and/or treat age-related degenerative diseases including dementia and movement disorders. Leveraging its proprietary drug discovery platform, VIT developed several first-in-class neuroprotective small molecules restoring cellular bioenergetics. VIT’s preclinical and clinical development plan is designed to quickly show target engagement using disease-relevant…
-
Corinne Lasmezas
Founder, CSO
-
Adam Milne
CEO
-
Eric Ende
Executive Chairman
Torpedo Bio
Twenty million Americans suffer from cancer. Lung cancer accounts for about 12% of new cancer cases and 20% of cancer deaths in the United States in 2024, with a survival rate of 20% (5 years). Current approved treatments for lung cancer include surgically removing the affected section of the lung, radiation, chemotherapy. In subsets of…
-
Leonardo Ferreira
Ph.D. Assistant Professor, MUSC
-
Nathan G. Dolloff
Ph.D. Associate Professor, MUSC, Founder, Leukogene Therapeutics, and CTO, Zucker Institute for Innovation Commercialization
-
Richard T. O’Neil
Ph.D. Assistant Professor, MUSC
-
Iosif M. Gershteyn
CEO, ImmuVia
RephImmune Biotechnology Inc.
RephImmune, is developing a novel cell therapy called RACE to provide late-stage cancer patients, who are running out of treatment options, with a low-dose, single-administration treatment that is more efficient, safer, and long-lasting. We compete in the growing cell therapy market, which last year was valued at $4.85 billion. Unlike convention CAR-T, our RACE offers…
-
Dr. Ming-Wei Chen
Ph.D.
-
Fangheng Zhou, M.S.
Co-Founder & CTO
Define Therapeutics Inc
Define Therapeutics Inc. discovers and develops innovative therapeutics for tough-to-treat prostate cancers such as castration-resistant prostate cancer (CRPC) and neuroendocrine prostate cancer (NEPC). Our novel strategy to modulate 2 or 3 key PARP-targets involved in the above pathogenesis with a single small-molecule is superior to the existing drugs. Using this approach, we plan to develop…
-
Dinesh Chimmanamada
Ph.D., Co-founder
-
Bryce M. Paschal
Ph.D., Co-founder
-
Aaron Goldman
Ph.D., Co-founder
Jaya Biosciences, Inc.
Jaya Biosciences is developing CNS-directed gene therapies for neurodegeneration, including Alzheimer’s disease. We are pursuing a novel paradigm based on the breakthrough discovery that mutations in certain lysosomal genes are highly enriched in patients with neurodegenerative phenotypes. To date, we have validated five lysosomal gene targets in vivo. Our lead program, JB111, is an experimental…
-
Pawel Krysiak
President & CEO
-
Mark Sands
Scientific Founder and SAB Chair
Cell BioEngines, Inc
“Cell BioEngines, Inc., is a clinical-stage biotech company focused on developing allogeneic ‘off-the-shelf’ stem cell and its derived therapies as ‘drugs’ for human disease treatment. Its lead product is currently in Phase 1 trials for the treatment of hematopoetiic neoplasms not curable with available therapies, particularly acute leukemia and myelodysplasia. It also has three pre-clinical…
-
Ajay Vishwakarma
DMD, MSc, MBA
Booster Biosciences
Booster Biosciences leverages novel biological models developed at Harvard Medical School to discover the mechanisms of resistance and engineer optimal therapeutics. Our portfolio of patented therapeutics target resistance to conventional and immuno-oncology drugs.
-
Aaron Goldman
Co-founder, Faculty and Instructor in Medicine, Harvard Medical School
-
Denton Chase
Co-founder
-
Arpita Kulkarni
Co-founder, Director, Harvard Medical School
DoriNano
DoriNano aims to harness the potential of DNA origami technology to develop safe, effective, and low-cost combination nanomedicines that have precise cellular targeting with minimal effective doses of cargo for serious diseases. The company’s platform sets out to solve the past limitations of nanoparticles for delivering therapeutic cargo, offering unique advantages such as programmable size…
-
Yang Claire Zeng, MD, PhD
Founder & CEO
Hestia Therapeutics
Hestia Therapeutics, lending its name from the Greek goddess of the hearth, aims to bring inflammatory cells into the tumor microenvironment to unleash anti-tumor effects from within. Currently, more than 70% of cancer patients have tumors that are shielded from the immune cells directed by checkpoint inhibitors to kill cancer cells, leading to disease progression.…
Koi Biotherapeutics
Koi Biotherapeutics is focused on solving a fundamental challenge in CAR T-cell therapy—the lack of long-term persistence of CAR T-cells post-infusion. Koi has developed a novel CAR-Enhancer protein that selectively targets CAR T-cells and promotes their development into memory cells, thereby enhancing their activity and in vivo persistence and eliminating the need for additional engineering…
-
Hamid Mahini, PhD
Co-Founder & CEO
-
Mohammad Rashidian, PhD
Scientific Founder, Assistant Professor at Dana-Farber Cancer Institute/Harvard Medical School